Promising cancer drug trial halted early – only 3 patients enrolled
NCT ID NCT04486391
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called tislelizumab, which helps the immune system fight cancer, against standard chemotherapy in people with Hodgkin lymphoma that returned or didn't respond to treatment. Only 3 people took part before the study was stopped early. Because of this, we don't have enough information to know if tislelizumab works better or is safer than chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (a type of immunotherapy that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with Hodgkin lymphoma that hasn't responded to other therapies.
- What could go wrong
- The trial was terminated early with only 3 participants, so we have very little data. It's unclear if tislelizumab is effective or safe compared to standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Quanzhou First Affliated Hospital of Fujian Medical University
Quanzhou, Fujian, 362000, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial